Jock Quentin, Levi Laura I, Lafaurie Matthieu, Goujon Annabelle, Mongiat Artus Pierre, Meria Paul, Desgrandchamps Francois, Masson Lecomte Alexandra, Seizilles de Mazancourt Emilien
Department of Urology, Saint Louis Hospital, Paris APHP, France.
Infectious Diseases Department, Université Paris Cité and Hôpital Saint-Louis and Lariboisière APHP, Paris, France.
World J Urol. 2025 May 19;43(1):316. doi: 10.1007/s00345-025-05671-9.
There are conflicting recommendations concerning the performance of a systematic urine culture (UC) prior to Bacillus Calmette Guerin (BCG) bladder instillations for non-muscle-invasive bladder tumor. The objective was to study the organizational impact of the UC performed before bladder instillations, defined as the number and proportion of BCG instillations postponed due to a positive urine culture result.
Induction BCG records in a single academic center between 2015 and 2020 were retrospectively reviewed. All patients had a UC prior to each instillation, treated if positive. Risk factors associated with the occurrence of a positive UC, an adverse event or postponement of instillation were studied.
A total of 156 patients were included, among which 68.9% of patients had at least one risk factor of UTI and 33% of patients presented at least one positive UC at induction. During BCG induction, 76/909 (8.4%) urine cultures performed were positive and 33% of patients had at least one postponement of BCG instillation. There were 64 instillations postponed, caused by untreated positive urine culture for 40 (62.5%) and absence of urine culture performed for 6 (9.4%) In multivariate analysis, only the presence of lower urinary tract symptoms was significantly associated with a risk of positive UC.
Positive UC during BCG instillations is a frequent event and a source of disorganization in BCG induction, with possible oncological consequences. A strategy of performing UC only in selected patients, could facilitate proper BCG administration and avoid unreasonable use of antibiotics.
对于非肌层浸润性膀胱肿瘤患者,在卡介苗(BCG)膀胱灌注前是否进行系统性尿培养(UC),存在相互矛盾的建议。本研究的目的是探讨膀胱灌注前进行尿培养对组织的影响,定义为因尿培养结果阳性而推迟的BCG灌注次数及比例。
回顾性分析2015年至2020年在单一学术中心进行诱导性BCG治疗的记录。所有患者在每次灌注前均进行尿培养,若结果为阳性则进行治疗。研究与尿培养阳性、不良事件或灌注推迟相关的危险因素。
共纳入156例患者,其中68.9%的患者至少有一个尿路感染危险因素,33%的患者在诱导期至少有一次尿培养阳性。在BCG诱导治疗期间,909次尿培养中有76次(8.4%)结果为阳性,33%的患者至少有一次BCG灌注推迟。共推迟64次灌注,其中40次(62.5%)是由于未治疗的尿培养阳性,6次(9.4%)是由于未进行尿培养。多因素分析显示,只有下尿路症状的存在与尿培养阳性风险显著相关。
BCG灌注期间尿培养阳性是常见事件,也是BCG诱导治疗中组织混乱的一个原因,可能产生肿瘤学后果。仅对选定患者进行尿培养的策略,有助于正确进行BCG给药,并避免不合理使用抗生素。